Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 16 Feb 2022
Pfizer and OPKO’s once weekly Ngenla (somatrogon) injection receives marketing authorisation in European Union for treatment of paediatric growth hormone deficiency
15 February 2022 - Pfizer and OPKO Health announced today that the European Commission has granted marketing authorisation for the next ...
Posted by Michael Wonder on 16 Feb 2022
Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus
16 February 2022 - Saphnelo is a first in class type I interferon receptor antibody and the only new medicine ...
Posted by Michael Wonder on 16 Feb 2022
European Medicines Agency approves Pfizer’s 20 valent pneumococcal conjugate vaccine against invasive pneumococcal disease and pneumonia in adults
15 February 2022 - Apexxnar [pneumococcal polysaccharide conjugate vaccine (20 valent, adsorbed)] is the first pneumococcal conjugate vaccine to help protect ...
Posted by Michael Wonder on 16 Feb 2022
Cardiosense receives FDA breakthrough device designation for algorithm to identify patients at risk of decompensated heart failure
15 February 2022 - Cardiosense announced today that the U.S. FDA has granted the company breakthrough device status for its ...
Posted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 16 Feb 2022
Rapid Medical receives FDA breakthrough device designation for vasospasm treatment
15 February 2022 - Comaneci temporarily expands blood vessels, recognised as novel device for life-threatening disease. ...
Posted by Michael Wonder on 16 Feb 2022
GE Healthcare's stress agent Rapiscan approved for use in stress cardiac magnetic resonance imaging
14 February 2022 - Already used in single photon emission computed tomography (SPECT) myocardial perfusion imaging for adult patients, Rapiscan is ...
Posted by Michael Wonder on 15 Feb 2022
Theradaptive wins additional FDA breakthrough designation for spinal fusion
15 February 2022 - Theradaptive announced that the U.S. FDA has granted breakthrough medical device designation for its OsteoAdapt SP Spinal ...
Posted by Michael Wonder on 15 Feb 2022
Office of Generic Drugs 2021 Annual Report
14 February 2022 - Ensuring high quality, affordable generic drugs are available to the American public. ...
Posted by Michael Wonder on 15 Feb 2022
Human medicines: highlights of 2021
15 February 2022 - In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance ...
Posted by Michael Wonder on 15 Feb 2022
WHO’s new International Classification of Diseases (ICD-11) comes into effect
11 February 2022 - The World Health Organization Eleventh Revision of the International Classification of Diseases (ICD-11) has now come ...
Posted by Michael Wonder on 15 Feb 2022
MTAA welcomes patent box legislation
11 February 2022 - MTAA has welcomed the introduction of the Government’s Patent Box Bill into the House of Representatives ...
Posted by Michael Wonder on 15 Feb 2022
Maine could lower cost of prescription drugs under new bill
15 February 2022 - An online public hearing for LD 1636 is being held on 15 February. ...
Posted by Michael Wonder on 15 Feb 2022
Biogen Alzheimer drug row augers flux in fast FDA approvals
14 February 2022 - Lawmakers could revamp the fast-track FDA process used to approve Biogen’s Alzheimer’s drug under must-pass legislation ...
Posted by Michael Wonder on 15 Feb 2022
Drug makers lose choline alfoscerate suit against Government
15 February 2022 - A court dismissed local drug makers’ appeal to nullify the Government’s push to negotiate the recollection ...